Evelyn Wong· @EvelynWongYT · X·· 18 小时前评分45
正文 · 机器翻译
Lisa Salvatore 的深入探讨：Temab-A + Bev 在 mCRC 中展现出潜力，但血液学毒性值得关注。
尚未解答的问题：Bev 能带来哪些额外获益？c-Met 能否指导患者选择？最佳剂量是多少？等待 III 期验证 #ESMO26 #ESMOAmbassadors @OncoAlert
23 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Evelyn Wong · x.com